Size Of Bristol's Sales Force Not An Issue In Sanofi Copromotion Deal, Exec Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers Squibb's discussions with Sanofi-Aventis regarding Plavix and Avapro copromotion will focus on business needs, not relative sales force sizes, Bristol said
You may also be interested in...
Sanofi, Bristol Discussing Changes To Avapro Agreement
Sanofi and Bristol-Myers Squibb are likely to make changes to the co-promotion for the antihypertensive Avapro, Sanofi said during an Aug. 31 analysts conference call
Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.
Astellas Ends Aczone Acne Treatment Collaboration Agreement With QLT
QLT now has worldwide marketing rights to the topical acne treatment. Astellas believes labeling proposed by FDA will limit the market profile for Aczone, the company said. Aczone’s user fee deadline is July 7.